U
Turn Therapeutics Inc. TTRX
$3.53 $0.030.86% NASDAQ
Recommendation
Prev Close
$3.50
Volume
21,382
Avg Vol (90D)
--
Market Cap
$103.06M
Dividend & Yield
--
52-Week Range
$2.57 - $26.50
P/E (TTM)
--
EPS (TTM)
-$0.14
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock
11/27/2025 - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Director Arthur Golden Buys 9,868 Shares
11/26/2025 - Ticker Report
Turn Therapeutics (NASDAQ:TTRX) Director Arthur Golden Purchases 9,868 Shares
11/26/2025 - MarketBeat
Arthur Golden Increases Stake in Turn Therapeutics Inc with Recent Share Purchase
11/26/2025 - GuruFocus
Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock
11/25/2025 - MarketBeat
Insider Buying: Arthur Golden Acquires Additional Shares of Turn Therapeutics Inc (TTRX)
11/24/2025 - GuruFocus
Turn Therapeutics (NASDAQ:TTRX) Releases Quarterly Earnings Results
11/14/2025 - MarketBeat
Turn Therapeutics (TTRX) Advances with Strategic Partnerships and Development Goals
11/13/2025 - GuruFocus
Turn Therapeutics reports Q3 EPS (7c) vs (3c) last year
11/13/2025 - The Fly
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/13/2025 - GuruFocus
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/13/2025 - Globe Newswire
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease ...
11/11/2025 - GuruFocus
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
11/11/2025 - Globe Newswire
Turn Therapeutics' GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine
11/11/2025 - Globe Newswire
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of ...
11/4/2025 - GuruFocus
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
11/4/2025 - Globe Newswire
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading ...
10/30/2025 - GuruFocus
Turn Therapeutics (TTRX) Partners with Medline for Global Supply Agreement
10/30/2025 - GuruFocus
Turn Therapeutics enters global supply, license agreement with Medline
10/30/2025 - TipRanks Financial Blog
Turn Therapeutics enters global supply, license agreement with Medline
10/30/2025 - The Fly
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
10/30/2025 - Globe Newswire
Turn Therapeutics Partners with Medline for Global Expansion
10/28/2025 - TipRanks Financial Blog
Video: Friday 10/24 Insider Buying Report: SNV, TTRX
10/24/2025 - Market News Video
Insider Buying: Arthur Golden Acquires 20,202 Shares of Turn Therapeutics Inc. (TTRX)
10/24/2025 - GuruFocus
Turn Therapeutics (TTRX) Advances Clinical Programs with Strategic Financial Flexibility
10/22/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$4.30M
Total Debt (Q)
$91.20K
Total Liabilities (Q)
$3.79M
Book Value Per Share (Q)
$0.018
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
--
7-Day Total Return
30.26%
30-Day Total Return
-28.54%
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
-49.57%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Nov 20, 2025 - $2.57
52-week High
Oct 09, 2025 - $26.50
Valuation
Market Cap
$103.06M - Micro Cap
Enterprise Value
$100.04M
Price/Sales (TTM)
--
Price/Book (Q)
194.44
Dividends and Shares
Shares Outstanding
27.98
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.turntherapeutics.com
Phone Number
818 546 4011
Address
250 N Westlake Blvd
Westlake Village, CA 91362
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed